Screener
Janux Therapeutics JANX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:18 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338078
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | 30,994 | 34,664 | 57,807 | 59,719 |
| General and administrative | 10,963 | 10,454 | 22,096 | 20,296 |
| Total operating expenses | 41,957 | 45,118 | 79,903 | 80,015 |
| Loss from operations | (31,690) | (45,118) | (65,903) | (80,015) |
| Other income: | ||||
| Interest income | 9,718 | 11,260 | 19,570 | 22,649 |
| Total other income | 9,718 | 11,260 | 19,570 | 22,649 |
| Net loss | $(21,972) | $(33,858) | $(46,333) | $(57,366) |
Item 1. Financial Statements.
FAQ
- What is Janux Therapeutics's operating income?
- Janux Therapeutics (JANX) reported operating income of -$31.69M in Q2 2026.
- How has Janux Therapeutics's operating income changed year-over-year?
- Janux Therapeutics's operating income increased by 29.8% year-over-year, from -$45.12M to -$31.69M.
- What is the long-term trend for Janux Therapeutics's operating income?
- Over 4 years (2021 to 2025), Janux Therapeutics's operating income has grown at a 47.9% compound annual growth rate (CAGR), from -$32.93M to -$157.67M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Janux Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude